PF 4518600

Drug Profile

PF 4518600

Alternative Names: PF-04518600; PF-8600

Latest Information Update: 27 Apr 2017

Price : $50

At a glance

  • Originator Pfizer
  • Class Antineoplastics
  • Mechanism of Action OX40 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 31 Mar 2017 University of Southern California and National Cancer Institute plan a phase II trial for Renal cell carcinoma (Metastatic disease, Combination therapy) in USA (NCT03092856)
  • 14 Nov 2016 Pfizer establishes CRADA with National Cancer Institute for the development of utomilumab, avelumab and PF 04518600 in Immunotherapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top